nach oben

Current Heart Failure Reports

Erschienen in:

03.07.2017 | Biomarkers of Heart Failure (W.H.W. Tang and J.L. Grodin, Section Editors)

The Basic Metabolic Profile in Heart Failure—Marker and Modifier

verfasst von: Ahmed Elfar, Kamalanathan K. Sambandam

Erschienen in: Current Heart Failure Reports | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The physiologic determinants of each of the components of the basic metabolic profile in patients with heart failure will be explored. Additionally, the review will discuss the prognostic value of alterations in the basic metabolic profile as well as their effects on management.

Recent Findings

Abnormalities in the basic metabolic profile have significant correlation with clinical outcomes and can modify treatment in heart failure. Hypochloremia has recently received increased attention for these reasons.

Summary

Elevated creatinine, increased blood urea nitrogen, hyponatremia, and hypochloremia correlate with worse mortality and diuretic resistance in heart failure. Hypokalemia, even when mild, has proven to be a worse clinical indicator than modest elevations in serum potassium. Hypochloremia is mechanistically linked to hyponatremia and metabolic alkalosis, but recent compelling data suggests that it can provide more discriminating prognostic information. Knowledge of the physiologic basis for each of these alterations informs their management.

Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Pysiol Rev. 2000;80(3):1107–213.

Kula AJ, Hanberg JS, Wilson FP, Brisco MA, Bellumkonda L, Jacoby D, et al. Influence of titration of neurohormonal antagonists and blood pressure reduction on renal function and decongestion in decompensated heart failure. Circ heart Failure. 2016;9(1):e002333.CrossRefPubMed

Forman DE, Butler J, Wang Y, Abraham WT, O’Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll of Cardiol. 2004;43:61–7.CrossRef

Damman K, Valente MAE, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;7:455–69.CrossRef

McAlister FA, Ezekowitz J, Tarantini L, Squire I, Komajda M, Bayes-Genis A, et al. Renal dysfunction in patients with preserved versus reduced ejection fraction: impact of the new chronic kidney disease-epidemiology collaboration group formula. Circ Heart Failure. 2012;5(3):309–14.CrossRefPubMed

Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13(6):422–30.CrossRefPubMed

Testani JM, Brisco MA, Turner JM, Spatz ES, Bellumkonda L, Parikh CR, et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014;7(2):261–770.CrossRefPubMed

Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circ. 2010;122(3):265–72.CrossRef

Greene SJ, Gheorghiade M, Vaduganathan M, Ambrosy AP, Mentz RJ, Subacius H, et al. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the Everest Trial. Eur J of Heart Fail. 2013;15(12):1401–11.CrossRef

10.

Oh J, Kang S-M, Hong N, Youn J-C, Han S, Jeon E-S, et al. Hemoconcentration is a good prognostic predictor for clinical outcomes in acute heart failure: data from the Korean Heart Failure (KorHF) Registry. Int J of Cardiol. 2013;168(5):4739–43.CrossRef

11.

• Van DM, Postmus D, Ponikowski P, Cleland JG, O’Connor CM, Cotter G, et al. The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol. 2013;61(19):1973–81. The above study performs a post hoc analysis of a large randomized controlled trial and reveals improved overall outcome with aggressive decongestion despite slight worsening in renal function with such a strategy. CrossRef

12.

Sands JM, Blount MA, Klein JD. Regulation of renal urea transport by vasopressin. Trans Am Clin Climatol Assoc. 2011;122:82–92.PubMedPubMedCentral

13.

Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319–31.CrossRefPubMed

14.

Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290(19):2581–7.CrossRefPubMed

15.

Filippatos G, Rossi J, Lloyd-Jones DM, Stough WG, Ouyang J, Shin DD, et al. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. J Card Fail. 2007 Jun;13(5):360–4.CrossRefPubMed

16.

Klein L, Massie BM, Leimberger JD, O’Connor CM, Piña IL, Adams KF, et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail. 2008 May;1(1):25–33.CrossRefPubMed

17.

Testani JM, Cappola TP, Brensinger CM, Shannon RP, Kimmel SE. Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. J Am Coll Cardiol. 2011;58(4):375–82.CrossRefPubMedPubMedCentral

18.

Edelman IS, Leibman J, O’meara MP, Birkenfeld LW. Interrelations between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium and total body water. J Clin Invest. 1958;37(9):1236–56.CrossRefPubMedPubMedCentral

19.

Verbrugge FH, Steels P, Grieten L, Nijst P, Tang WHW, Mullens W. Hyponatremia in acute decompensated heart failure: depletion versus dilution. J Am Coll Cardiol. 2015;65(5):480–92.CrossRefPubMed

20.

Nguyen MK, Kurtz I. Role of potassium in hypokalemia-induced hyponatremia: lessons learned from the Edelman equation. Clin Exp Nephrol. 2004;8(2):98–102.CrossRefPubMed

21.

Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O’Connor CM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28(8):980–8.CrossRefPubMed

22.

Klein L, O’Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005;111(19):2454–60.CrossRefPubMed

23.

Gandhi S, Mosleh W, Myers RBH. Hypertonic saline with furosemide for the treatment of acute congestive heart failure: a systematic review and meta-analysis. Int J Cardiol. 2014;173(2):139–45.CrossRefPubMed

24.

Hayes CP, McLeod ME, Robinson RR. An extrarenal mechanism for the maintenance of potassium balance in severe chronic renal failure. Trans Assoc Am Phys. 1967;80:207–16.PubMed

25.

Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, et al. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail. 2014;7(4):573–9.CrossRefPubMed

26.

Huang C-L, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol. 2007;18(10):2649–52.CrossRefPubMed

27.

Hoss S, Elizur Y, Luria D, Keren A, Lotan C, Gotsman I. Serum potassium levels and outcome in patients with chronic heart failure. Am J Cardiol. 2016;118(12):1868–74.CrossRefPubMed

28.

Salah K, Pinto YM, Eurlings LW, Metra M, Stienen S, Lombardi C, et al. Serum potassium decline during hospitalization for acute decompensated heart failure is a predictor of 6-month mortality, independent of N-terminal pro-B-type natriuretic peptide levels: an individual patient data analysis. Am Heart J. 2015;170(3):531–42.CrossRefPubMed

29.

Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation. 1998;98(15):1510–6.CrossRefPubMed

30.

WWEIA Data Tables: USDA ARS. [Internet]. [cited 2017Apr24]. Available from: https://www.ars.usda.gov/northeast-area/beltsville-md/beltsville-human-nutrition-research-center/food-surveys-research-group/docs/wweia-data-tables/.

31.

Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang I-Z, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32(7):820–8.CrossRefPubMedPubMedCentral

32.

Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015;17(10):1057–65.CrossRefPubMedPubMedCentral

33.

• Hanberg JS, Rao V, Ter Maaten JM, Laur O, Brisco MA, Perry Wilson F, et al. Hypochloremia and diuretic resistance in heart failure: mechanistic insights. Circ Heart Fail. 2016; 9(8). The above analysis provides the most complete description to date of the hypochloremic heart failure patient phenotype.

34.

Gomez H, Kellum JA. Understanding acid base disorders. Crit Care Clin. 2015;31(4):849–60.CrossRefPubMed

35.

Grodin JL, Simon J, Hachamovitch R, Wu Y, Jackson G, Halkar M, et al. Prognostic role of serum chloride levels in acute decompensated heart failure. J Am Coll Cardiol. 2015;66(6):659–66.CrossRefPubMed

36.

Grodin JL, Verbrugge FH, Ellis SG, Mullens W, Testani JM, Tang WHW. Importance of abnormal chloride homeostasis in stable chronic heart failure. Circ Heart Fail. 2016;9(1):e002453.CrossRefPubMedPubMedCentral

37.

Ter Maaten JM, Damman K, Hanberg JS, Givertz MM, Metra M, O’Connor CM, et al. Hypochloremia, diuretic resistance, and outcome in patients with acute heart failure. Circ Heart Fail. 2016; 9(8).

38.

Testani JM, Hanberg JS, Arroyo JP, Brisco MA, Ter Maaten JM, Wilson FP, et al. Hypochloraemia is strongly and independently associated with mortality in patients with chronic heart failure. Eur J Heart Fail. 2016;18(6):660–8.CrossRefPubMedPubMedCentral

39.

Grodin JL, Sun J-L, Anstrom KJ, Chen HH, Starling RC, Testani JM, et al. Implications of serum chloride homeostasis in acute heart failure (from ROSE-AHF). Am J Cardiol. 2017;119(1):78–83.CrossRefPubMed

40.

Ponce-Coria J, San-Cristobal P, Kahle KT, Vazquez N, Pacheco-Alvarez D, de Los HP, et al. Regulation of NKCC2 by a chloride-sensing mechanism involving the WNK3 and SPAK kinases. Proc Natl Acad Sci U S A. 2008;105(24):8458–63.CrossRefPubMedPubMedCentral

41.

Bazúa-Valenti S, Chávez-Canales M, Rojas-Vega L, González-Rodríguez X, Vázquez N, Rodríguez-Gama A, et al. The effect of WNK4 on the Na+-Cl- cotransporter is modulated by intracellular chloride. J Am Soc Nephrol. 2015;26(8):1781–6.CrossRefPubMed

42.

Galla JH, Bonduris DN, Luke RG. Effects of chloride and extracellular fluid volume on bicarbonate reabsorption along the nephron in metabolic alkalosis in the rat. Reassessment of the classical hypothesis of the pathogenesis of metabolic alkalosis. J Clin Invest. 1987;80(1):41–50.CrossRefPubMedPubMedCentral

Titel: The Basic Metabolic Profile in Heart Failure—Marker and Modifier
verfasst von: Ahmed Elfar
Kamalanathan K. Sambandam
Publikationsdatum: 03.07.2017
Verlag: Springer US
Erschienen in: Current Heart Failure Reports / Ausgabe 4/2017
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-017-0344-x

Neu im Fachgebiet Kardiologie

23.04.2024 | Ablationstherapie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The Basic Metabolic Profile in Heart Failure—Marker and Modifier

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities

Treatment of Hyperkalemia in Heart Failure

Towards Holistic Heart Failure Management—How to Tackle the Iron Deficiency Epidemic?

Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT

SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys

Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure

Neu im Fachgebiet Kardiologie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Kardiologie